S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   290.84 (-5.01%)
AAPL   140.65 (-5.76%)
MSFT   253.95 (-4.82%)
FB   192.24 (-5.12%)
GOOGL   2,237.00 (-3.97%)
AMZN   2,141.77 (-7.18%)
TSLA   708.00 (-7.04%)
NVDA   168.98 (-7.04%)
BABA   87.35 (-5.04%)
NIO   15.86 (-4.63%)
AMD   96.21 (-6.11%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.25 (-1.56%)
GE   75.26 (-1.49%)
F   12.79 (-5.47%)
DIS   104.33 (-3.97%)
AMC   12.80 (-0.78%)
PFE   50.41 (-1.81%)
PYPL   77.19 (-3.21%)
NFLX   177.18 (-7.02%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   290.84 (-5.01%)
AAPL   140.65 (-5.76%)
MSFT   253.95 (-4.82%)
FB   192.24 (-5.12%)
GOOGL   2,237.00 (-3.97%)
AMZN   2,141.77 (-7.18%)
TSLA   708.00 (-7.04%)
NVDA   168.98 (-7.04%)
BABA   87.35 (-5.04%)
NIO   15.86 (-4.63%)
AMD   96.21 (-6.11%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.25 (-1.56%)
GE   75.26 (-1.49%)
F   12.79 (-5.47%)
DIS   104.33 (-3.97%)
AMC   12.80 (-0.78%)
PFE   50.41 (-1.81%)
PYPL   77.19 (-3.21%)
NFLX   177.18 (-7.02%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   290.84 (-5.01%)
AAPL   140.65 (-5.76%)
MSFT   253.95 (-4.82%)
FB   192.24 (-5.12%)
GOOGL   2,237.00 (-3.97%)
AMZN   2,141.77 (-7.18%)
TSLA   708.00 (-7.04%)
NVDA   168.98 (-7.04%)
BABA   87.35 (-5.04%)
NIO   15.86 (-4.63%)
AMD   96.21 (-6.11%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.25 (-1.56%)
GE   75.26 (-1.49%)
F   12.79 (-5.47%)
DIS   104.33 (-3.97%)
AMC   12.80 (-0.78%)
PFE   50.41 (-1.81%)
PYPL   77.19 (-3.21%)
NFLX   177.18 (-7.02%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   290.84 (-5.01%)
AAPL   140.65 (-5.76%)
MSFT   253.95 (-4.82%)
FB   192.24 (-5.12%)
GOOGL   2,237.00 (-3.97%)
AMZN   2,141.77 (-7.18%)
TSLA   708.00 (-7.04%)
NVDA   168.98 (-7.04%)
BABA   87.35 (-5.04%)
NIO   15.86 (-4.63%)
AMD   96.21 (-6.11%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.25 (-1.56%)
GE   75.26 (-1.49%)
F   12.79 (-5.47%)
DIS   104.33 (-3.97%)
AMC   12.80 (-0.78%)
PFE   50.41 (-1.81%)
PYPL   77.19 (-3.21%)
NFLX   177.18 (-7.02%)
OTCMKTS:MNKKQ

Mallinckrodt (MNKKQ) Stock Forecast, Price & News

$0.08
+0.00 (+2.04%)
(As of 05/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.07
$0.09
50-Day Range
$0.06
$0.12
52-Week Range
$0.05
$0.59
Volume
333,152 shs
Average Volume
275,779 shs
Market Capitalization
$6.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.71
30 days | 90 days | 365 days | Advanced Chart
Receive MNKKQ News and Ratings via Email

Sign-up to receive the latest news and ratings for Mallinckrodt and its competitors with MarketBeat's FREE daily newsletter.

Mallinckrodt logo

About Mallinckrodt

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland. On October 12, 2020, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Headlines

Mallinckrodt Provides a Regulatory Update on Terlipressin
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:MNKKQ
Fax
N/A
Employees
2,800
Year Founded
N/A

Sales & Book Value

Annual Sales
$2.21 billion
Book Value
$3.70 per share

Profitability

Net Income
$-717.40 million
Pretax Margin
-37.13%

Debt

Price-To-Earnings

Miscellaneous

Free Float
81,709,000
Market Cap
$6.79 million
Optionable
Optionable

Company Calendar

Today
5/18/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.13 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -













Mallinckrodt (OTCMKTS:MNKKQ) Frequently Asked Questions

Who are Mallinckrodt's key executives?
Mallinckrodt's management team includes the following people:
  • Mr. Mark Christopher Trudeau, Pres, CEO & Director (Age 61, Pay $8.98M)
  • Mr. Hugh M. O'Neill, Exec. VP & Chief Commercial and Operations Officer (Age 59, Pay $3.29M)
  • Dr. Steven J. Romano M.D., Exec. VP & Chief Scientific Officer (Age 63, Pay $3.37M)
  • Mr. Bryan M. Reasons, Exec. VP & CFO (Age 55)
  • Mr. Daniel J. Speciale CPA, CPA, Global Corp. Controller & Chief Investor Relations Officer
  • Mr. Mark J. Casey, Exec. VP & Chief Legal Officer (Age 59)
  • Ms. Kassie Harrold, Sr. VP & Chief Compliance Officer (Age 42)
  • Mr. Ian J. Watkins, Exec. VP & Chief HR Officer (Age 59)
  • Mark Tyndall, Sr. VP of Gov. Affairs & Chief Counsel of Litigation
  • Mr. John E. Einwalter, VP & Treasurer
What is Mallinckrodt's stock symbol?

Mallinckrodt trades on the OTCMKTS under the ticker symbol "MNKKQ."

How do I buy shares of Mallinckrodt?

Shares of MNKKQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mallinckrodt's stock price today?

One share of MNKKQ stock can currently be purchased for approximately $0.08.

How much money does Mallinckrodt make?

Mallinckrodt has a market capitalization of $6.79 million and generates $2.21 billion in revenue each year.

How many employees does Mallinckrodt have?

Mallinckrodt employs 2,800 workers across the globe.

What is Mallinckrodt's official website?

The official website for Mallinckrodt is www.mallinckrodt.com.

How can I contact Mallinckrodt?

Mallinckrodt's mailing address is COLLEGE BUSINESS & TECHNOLOGY PARK CRUISERATH BLANCHARDSTOWN, DUBLIN 15 L2, D15. The company can be reached via phone at (531) 696-0000 or via email at [email protected].

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.